JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and

Engineers Gate Manager LP lifted its stake in shares of Scholar Rock Holding Corporation (NASDAQ: SR

Scholar Rock Holding Corporation maintains a "Strong Buy" rating following FDA approval of ISEMBYLD

Evercore ISI Group analyst Cory Kasimov maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outpe

Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overwei

Jefferies analyst Amy Li maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the p

Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mix

Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform

Analysts cut Exodus’ target, raised targets for Teledyne, Roblox, Scholar Rock, Zebra, Agilon, SM En

Barclays analyst Etzer Darout downgrades Scholar Rock Holding (NASDAQ:SRRK) from Overweight to Eq

Markets are rattled ahead of Wednesday's Fed decision, and Wall Street analysts are making bold move

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK)

Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SM

Raymond James analyst Gary Nachman maintains Scholar Rock Holding (NASDAQ:SRRK) with a Strong Buy

BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform a

Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with

Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raise

The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Ro

FDA approves Scholar Rock Isembyld to treat spinal muscular atrophy in adults and pediatric patients

Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperfor

Scholar Rock on Monday ​set a list ‌price of $11,659 per single-use vial ​for its ​newly approved sp

Shares of Scholar Rock Holding Corp (NASDAQ:SRRK) rose sharply in pre-market trading after the compa

Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premark

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK)

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of

FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facilityCompany is prep

JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and

Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping th

Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperfor

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK)

Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raise

Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part o

Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.84) per share which beat the ana

Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperfor

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of

Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK)

Canaccord Genuity analyst Gary Nachman initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) w

Top Wall Street analysts changed their outlook on top names. For a complete view of all rating chang

Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen

Apitegromab BLA resubmission includes Catalent Indiana LLC (part of Novo Nordisk) and second U.S.-ba

JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and

Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raise

BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform a

Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:SRRK) with

Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK)